

NOTIFICATION OF UPCOMING EXPIRY OF LISTED OPTIONS

MELBOURNE, Australia, 29 May 2025: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, advises that the attached letter has been sent to registered holders of listed options (ASX:DXBO) (**Listed Options**) which are exercisable at \$0.154 on or before 5pm (AEST) on 30 June 2025 (**Expiry Date**).

An example of the form of letter (including an example **Notice of Exercise**) that will be personalised and sent to each holder of Listed Options is enclosed with this announcement.

Official quotation of the Listed Options on ASX will cease at close of trading on 24 June 2025, being four business days before the Expiry Date.

Holders of the Listed Options can exercise all or part of their Listed Options prior to the Expiry Date by completing a Notice of Exercise as attached to the letter (also accessible via the Automic Portal as described in the attached letter) specifying the number of Listed Options being exercised and by making payment in cleared funds of the total exercise price for the number of Listed Options being exercised. Further instructions are provided in the attached letter. There is no obligation on a holder of Listed Options to exercise a certain number of Listed Options, or any at all. If you require assistance to access your Notice of Exercise please contact Automic on:

- Telephone (within Australia): 1300 288 664
- Telephone (outside Australia): +61 2 9698 5414
- Email: hello@automicgroup.com.au

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [X](#) and [LinkedIn](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for respiratory disease. DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

About DMX 200

DMX 200 is the adjunct therapy of a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker - the standard of care treatment for hypertension and kidney disease. DMX 200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2042, in addition to any exclusivity period that may apply in key territories. In 2020, Dimerix completed two Phase 2 studies: one in FSGS and one in diabetic kidney disease, following a successful Phase 2a trial in patients with a range of chronic kidney diseases in 2017. No significant adverse safety events were reported in any trial, and all studies resulted in encouraging data that could provide meaningful clinical outcomes for patients with kidney disease.

About FSGS

FSGS is a rare, serious kidney disorder characterized by progressive scarring (sclerosis) in parts of the glomeruli—the kidney's filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.¹ There are no therapies specifically approved for FSGS anywhere in the world, and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,² underscoring the urgent need for new, disease-modifying treatments. Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for various development incentives including: seven years (FDA) and ten years (EMA) of market exclusivity if regulatory approval is received, exemption from certain application fees, and a fast-tracked regulatory pathway to approval. Dimerix reported positive Phase 2a data in FSGS patients in July 2020.

References

-
- 1 Guruswamy Sangameswaran KD, Baradhi KM. (2021) *Focal Segmental Glomerulosclerosis*, online: <https://www.ncbi.nlm.nih.gov/books/NBK532272/>
 - 2 *Front. Immunol.*, (July 2019) | <https://doi.org/10.3389/fimmu.2019.01669>

29 May 2025

Dear Option Holder

UPCOMING EXPIRY OF LISTED OPTIONS (ASX:DXBO)

We are writing to you as a registered holder of listed options (ASX: DXBO) (**Listed Options**) in Dimerix Limited (**Dimerix** or **Company**) to remind you that the Listed Options you hold will expire at 5:00pm (AEST) on 30 June 2025 (**Expiry Date**). Details of how to exercise your Listed Options (at the exercise price of \$0.154 (15.4 cents) per Listed Option) into fully paid ordinary shares in the Company (**Shares**) prior to the Expiry Date are set out below.

There is no obligation upon Option holders to exercise some or all of their Listed Options, or any at all. The courses of actions available to you as a holder of these soon to expire Listed Options are to:

- a) **Exercise your Listed Options:** Should you wish to exercise some or all of your Listed Options, you must complete the personalised "Notice of Exercise of Options" form (**Notice of Exercise**) accompanying this letter (or as can be downloaded from the Automic Portal, refer below) and provide the completed Notice of Exercise together with payment in cleared funds of \$0.154 per Listed Option being exercised in accordance with the instruction set out in the Notice of Exercise. Your completed Notice of Exercise and payment (in cleared funds) must be received by no later than 5:00pm (AEST) on the Expiry Date, failing which Listed Options shall lapse. Instructions regarding methods of payment are included in the Notice of Exercise.
- b) **Sell your Options:** Please note that official quotation of the Listed Options on ASX will cease at close of trading on 24 June 2025, being four business days before the Expiry Date. Listed Options will not be able to be traded on ASX after this time.
- c) **Do nothing and allow your Options to expire:** If you do not exercise or sell your Listed Options in the manner described above, those Listed Options will expire at 5:00pm (AEST) on the Expiry Date and your right to exercise Listed Options and be issued Shares at \$0.154 per Share in respect of those Listed Options will lapse.

Notice of Exercise – Instructions

Your Notice of Exercise can also be accessed online through the Automic Portal. Please refer below for further instructions:

- i. Log in to the Automic portal via: <https://investor.automic.com.au/#/loginsah>
- ii. Navigate to the Correspondence heading.
- iii. Click on the "Download" icon under the heading 'Correspondence History' to view a copy of your 'Exercise Form'.

If you do not have a log in, please follow the below steps to register:

- i. Visit <https://investor.automic.com.au/#/signup>
- ii. Enter "Dimerix Limited" in the Company Name Field ensuring that you select the Company name from the drop down list
- iii. Enter your Securityholder Reference Number (Holding Number) as shown in your holding statement accessed above
- iv. Enter your postcode OR country of residence (only if outside Australia)

- v. Tick the box "I'm not a robot" and then select "Next"
- vi. Complete the prompts to set up your username and password details.
- 2. Follow the payment instructions as outlined on your Notice of Exercise of Options

In accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, the Company provides the following information:

- a) the name of the holder of the Listed Options, the number of Listed Options held and the number of Shares to be issued on exercise of the Listed Options is set out in the personalised Notice of Exercise accompanying this letter;
- b) the exercise price of the Listed Options is \$0.154 per Listed Option;
- c) the Listed Options must be exercised and payment (in cleared funds) received by no later than 5:00pm (AEST) on 30 June 2025 (being the Expiry Date);
- d) if you do not exercise your Listed Options in the manner described above, they will expire at 5:00pm (AEST) on the Expiry Date and your right to exercise your Listed Options and be issued Shares at \$0.154 per Share in respect of those Listed Options will lapse;
- e) official quotation of the Listed Options on ASX will cease at close of trading on 24 June 2025, being four business days before the Expiry Date;
- f) the market price of Shares on ASX on 28 May 2025 was \$0.585, being the closing price of Shares on ASX prior to the date of this letter;
- g) during the 3 months preceding the date of this letter:
 - i. the highest market sale price of Shares on ASX was \$0.755 on 02 May 2025; and
 - ii. the lowest market sale price of Shares on ASX was \$0.35 on 09 April 2025.
- h) as at the date of this notice, there are no underwriting agreements in relation to the Options.

If you have any questions regarding the exercise of your Listed Options or need assistance with accessing your Holding Number, please contact Automic on:

- Telephone (within Australia): 1300 288 664
- Telephone (outside Australia): +61 2 9698 5414
- Email: hello@automicgroup.com.au

Yours sincerely,



Dr Nina Webster
CEO & Managing Director

SRN/HIN:

Security Code: DXBO

Number of Options held:

Option Expiry Date: 30 June 2025

Exercise Price: \$0.154

Total Amount payable (exercising in full):

NOTICE OF EXERCISE OF OPTIONS

By making a BPAY® or EFT payment or returning this form together with a confirmation of your BPAY® or EFT payment, I/we hereby exercise the following number of Options and make payment in Australian currency for the amount payable. I/We will be allotted Ordinary Shares calculated on the basis of one (1) Ordinary Share for every one (1) Option exercised. I/We agree to accept such Shares subject to the Constitution of Dimerix Limited.

1. Number of Options to be Exercised

 , ,

Total payment required @ \$0.154 per Option

A\$, , .

If the dollar amount paid results in a fraction of a share then the shares allotted will be rounded down.

2. Payment: You can pay either by BPAY®, EFT

Option A – BPAY®



Biller Code: 410449

Ref No:

© Registered to BPAY Pty Ltd ABN 69079137518

Contact your financial institution to make your payment from your cheque or savings account.

Note: You do not need to return this form if you have made payment via BPAY®. Your BPAY® reference number will process your payment to your Options exercise electronically.

You should check the processing cut-off time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Share Registry in time.

Option B – Electronic Funds Transfer (EFT)

The unique payment reference number which has been assigned to your Application is: **[holderId]-9253-DXBO**

Funds are to be deposited directly to following bank account:

Account name: Automic Pty Ltd

Account BSB: 036-051

Account number: 593533

Swift Code: WPACAU2S

IMPORTANT: You must quote your unique reference number as your payment reference/ description when processing your EFT payment. Failure to do so may result in your funds not being allocated to exercise the Options and shares subsequently not issued.

Note: You do not need to return this Form if you have made payment via EFT. Your unique payment reference number will process your payment to your Options exercise electronically.

3. Contact details & Elect to be an e-Shareholder

Telephone Number

()

Email Address

Contact Name (PLEASE PRINT)

As part of the Company's commitment to improving shareholder value, we encourage you to elect to receive all shareholder communications electronically.

By choosing this option you will:

- Support the company that you hold an ownership in by helping us to reduce the thousands of dollars spent on printing and postage costs each year;
- Receive your investor communications faster and in a more secure way; and
- Help the environment through the need for less paper.

SIMPLY SCAN THE QR CODE TO VISIT [HTTPS://INVESTOR.AUTOMIC.COM.AU](https://investor.automic.com.au) AND UPDATE YOUR COMMUNICATION PREFERENCE .

